Sign In
Buy DXCM
$82.66
-4.28 (-4.92%)
At Close: Aug 05, 2026
Class Action Filed Against DexCom, Inc. (DXCM) - October 21, 2024 Deadline to Join – Contact Levi & Korsinsky
08:45pm, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follo
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
08:41pm, Wednesday, 21'st Aug 2024
LOS ANGELES--(BUSINESS WIRE)--DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against DexCom Inc.
08:20pm, Wednesday, 21'st Aug 2024
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom In
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom Lawsuit – DXCM
06:00pm, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follo
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inc
Investors in DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - DXCM
05:15pm, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follo
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follo
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of DexCom, Inc.
ATTENTION DXCM SHAREHOLDERS: Investors who Lost Money on DexCom, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
11:15am, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of fede
Shareholders Are Invited By The Schall Law Firm To Participate In The Investigation Into DexCom Inc For Potential Securities Fraud
11:00am, Wednesday, 21'st Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of fede
RADNOR, Pa. , Aug. 21, 2024 /PRNewswire/ -- law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of in
DexCom, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by DexCom (DXCM)
07:30am, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of fede
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal
Is It Time to Buy July's Worst-Performing S&P 500 Stocks?
06:30am, Wednesday, 21'st Aug 2024
July saw the market retreat quite a bit from its height in mid-July. DexCom's outlook disappointed investors -- and the caution may be warranted.
